A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2018

At a glance

  • Drugs VT 1161 (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REVIVE
  • Sponsors Viamet Pharmaceuticals
  • Most Recent Events

    • 10 Mar 2018 Results (n=215) assessing efficacy and safety of 4 dosing regimens of oral VT-1161 compared to placebo in women with recurrent vulvovaginal candidiasis, were published in the American Journal of Obstetrics and Gynecology.
    • 19 Dec 2017 Last checked against the ClinicalTrials.gov record.
    • 23 Oct 2017 According to a Viamet Pharmaceuticals media release, results from this trial will be presented at the International Society for Infectious Diseases in Obstetrics and Gynaecology (ISIDOG) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top